SIRION Biotech’s adenovirus technology allows for overexpression of BACH2: BACH2 plays role in type 1 Diabetes by regulating pancreatic β-cells
American Diabetes Association posts publication presenting clarification on the BACH2 mecha-nism to contribute to diabetes
SIRION BIOTECH GmbH
SIRION Biotech started in Munich in 2007 with the idea of enabling novel cell models closer to reality than ever before. This required the assembly of an all-encompassing, novel viral vector platform. Both, designing de novo viral vectors and the subsequent creation of custom cell models will pave the way for superior compound development in the life sciences. SIRION's technologies have been validated in over 300 single projects with more than 100 academic and industrial partners. As a result, cell models for drug discovery and development have become highly reliable, as have the use of new viral vectors in gene therapy and vaccine studies.